News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on IDT Australia.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: IDT on strong growth trajectory, Paradigm smashed 30pc on cap raise
News
Top 10 at 10: WA1 scales new heights, REZ hits a shallow nickel orebody in the making
Health & Biotech
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Health & Biotech
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales
Health & Biotech
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
Health & Biotech
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
News
CLOSING BELL: Aussies find a cost of living crisis fix, by stealing everything not nailed down
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
Health & Biotech
ASX Health Stocks: Patrys wins fresh grant, IDT does not and Next Science is off to sell stuff in Canada
Health & Biotech
Who got what in the healthcare budget, and which ASX stocks could benefit
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech
ASX Health Stocks: ImpediMed extends SOZO contract with global pharma AstraZeneca
Health & Biotech
Check Up: Moderna trials mRNA-based HIV vaccine, while these ASX biotechs get patents
Health & Biotech
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
Health & Biotech
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
Health & Biotech
What’s the best pot stock of 2021? And who’s targeting market domination in 2022?
Health & Biotech
